Melanoma Trial, Recruiting NCT07206017 Sponsor: University Medical Center Groningen Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT07206017
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People who understand the study and are able to sign a written consent form
  • People who have had surgery for an intermediate to high-risk skin melanoma at a specific stage, with no sign of the disease remaining after surgery (confirm with trial site for exact staging details)
  • People who are able to read and speak Dutch
  • People who are willing and able to travel to the UMCG (the study hospital) for visits
  • People who are willing to continue their normal daily habits and lifestyle throughout the study

Who may not be able to join:

  • People who are currently receiving adjuvant (additional cancer) treatment at the same time as the study (treatment after the study period has ended is allowed)
  • People with certain existing health conditions that could affect study results, such as type 2 diabetes, heart disease, kidney disease, or an autoimmune disease
  • People with a significant or unstable gut-related condition, such as coeliac disease, inflammatory bowel disease, short bowel syndrome, or acute or chronic pancreatitis
  • People who have had an ileostomy or colostomy (surgically created openings in the abdomen for waste removal)
  • People who have used antibiotics in the three months before joining the study
  • People who use prednisolone or other medications that suppress the immune system
  • People who rely on tube feeding or similar assisted feeding methods
  • People who are pregnant or breastfeeding
  • People who are currently participating in another interventional research study at the same time
  • People who are unable or unwilling to follow the study rules

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: G. A.P. Hospers, MD, PhD, University Medical Center Groningen

Phone: +31 50 361 2821

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
26 March 2025
Est. completion
25 March 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Effect of a high fiber prebiotic vegetable (WholeFiber) on fecal SCFA levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov